- Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
[作者：Bringhen, S; Larocca, A; Rossi, D; Cavalli, M; Genuardi, M; Ria, R; Gentili, S; Patriarca, F; Nozzoli, C; Levi, A; Guglielmelli, T; Benevolo, G; Callea, V; Rizzo, V; Cangialosi, C; Musto, P; De Rosa, L; Liberati, AM; Grasso, M; Falcone, AP; Evangelista, A; Cavo, M; Gaidano, G; Boccadoro, M; Palumbo, A,期刊：Blood, 页码：4745-4753 , 文章类型： Article，,卷期：2010年116-23]
- In a recent phase 3 trial, bortezomib-melphalan-prednisone-thalidomide followed by maintenance treatment with bortezomib-thalidomide demonstrated superior efficacy compared with bortezomib-melphalan-prednisone. To decrea...
- Who is fit for allogeneic transplantation?
[作者：Deeg, HJ; Sandmaier, BM,期刊：Blood, 页码：4762-4770 , 文章类型： Article，,卷期：2010年116-23]
- The use of allogeneic hematopoietic cell transplantation (HCT) has expanded progressively, facilitated by the increasing availability of unrelated donors and cord blood, and the inclusion of older patients as transplanta...
- Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance
[作者：Moreno, C; Hodgson, K; Ferrer, G; Elena, M; Filella, X; Pereira, A; Baumann, T; Montserrat, E,期刊：Blood, 页码：4771-4776 , 文章类型： Article，,卷期：2010年116-23]
- We analyzed prevalence, characteristics, clinical correlates, and prognostic significance of autoimmune cytopenia in patients with chronic lymphocytic leukemia. Seventy of 960 unselected patients (7%) had autoimmune cyto...
- Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
[作者：Moreau, P; Jaccard, A; Benboubker, L; Royer, B; Leleu, X; Bridoux, F; Salles, G; Leblond, V; Roussel, M; Alakl, M; Hermine, O; Planche, L; Harousseau, JL; Fermand, JP,期刊：Blood, 页码：4777-4782 , 文章类型： Article，,卷期：2010年116-23]
- New treatment options are required for primary systemic amyloid light chain (AL) amyloidosis. This phase 1/2 dose-escalation study aimed to determine the maximum tolerated dose (MTD) of lenalidomide in combination with m...
- Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias
[作者：Gomez-Almaguer, D; Solano-Genesta, M; Tarin-Arzaga, L; Herrera-Garza, JL; Cantu-Rodriguez, OG; Gutierrez-Aguirre, CH; Jaime-Perez, JC,期刊：Blood, 页码：4783-4785 , 文章类型： Article，,卷期：2010年116-23]
- Treatment of autoimmune cytopenias remains unsatisfactory for patients refractory to first-line management. We evaluated the safety and efficacy of low-dose rituximab plus alemtuzumab in patients with steroid-refractory ...
- Retinoic acid enhances the generation of hematopoietic progenitors from human embryonic stem cell-derived hemato-vascular precursors
[作者：Yu, C; Liu, YX; Miao, ZC; Yin, M; Lu, W; Lv, YX; Ding, MX; Deng, HK,期刊：Blood, 页码：4786-4794 , 文章类型： Article，,卷期：2010年116-23]
- Current induction schemes directing hematopoietic differentiation of human embryonic stem cells (hESCs) are not well defined to mimic the sequential stages of hematopoietic development in vivo. Here, we report a 3-stage ...
- Inducible Fli-1 gene deletion in adult mice modifies several myeloid lineage commitment decisions and accelerates proliferation arrest and terminal erythrocytic differentiation
[作者：Starck, J; Weiss-Gayet, M; Gonnet, C; Guyot, B; Vicat, JM; Morle, F,期刊：Blood, 页码：4795-4805 , 文章类型： Article，,卷期：2010年116-23]
- This study investigated the role of the ETS transcription factor Fli-1 in adult myelopoiesis using new transgenic mice allowing inducible Fli-1 gene deletion. Fli-1 deletion in adult induced mild thrombocytopenia associa...
- FIP200 is required for the cell-autonomous maintenance of fetal hematopoietic stem cells
[作者：Liu, F; Lee, JY; Wei, HJ; Tanabe, O; Engel, JD; Morrison, SJ; Guan, JL,期刊：Blood, 页码：4806-4814 , 文章类型： Article，,卷期：2010年116-23]
- Little is known about whether autophagic mechanisms are active in hematopoietic stem cells (HSCs) or how they are regulated. FIP200 (200-kDa FAK-family interacting protein) plays important roles in mammalian autophagy an...
- Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs
[作者：Winkler, IG; Sims, NA; Pettit, AR; Barbier, V; Nowlan, B; Helwani, F; Poulton, IJ; van Rooijen, N; Alexander, KA; Raggatt, LJ; Levesque, JP,期刊：Blood, 页码：4815-4828 , 文章类型： Article，,卷期：2010年116-23]
- In the bone marrow, hematopoietic stem cells (HSCs) reside in specific niches near osteoblast-lineage cells at the endosteum. To investigate the regulation of these endosteal niches, we studied the mobilization of HSCs i...
|